New Zealand markets closed

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
692.80+9.36 (+1.37%)
At close: 04:00PM EDT
693.00 +0.20 (+0.03%)
After hours: 05:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 72.41B
Enterprise value 68.06B
Trailing P/E 9.35
Forward P/E 15.70
PEG ratio (5-yr expected) 5.92
Price/sales (ttm)4.51
Price/book (mrq)3.64
Enterprise value/revenue 4.12
Enterprise value/EBITDA 7.18

Trading information

Stock price history

Beta (5Y monthly) 0.24
52-week change 336.03%
S&P500 52-week change 3-3.48%
52-week high 3747.42
52-week low 3497.22
50-day moving average 3680.75
200-day moving average 3638.80

Share statistics

Avg vol (3-month) 3644.12k
Avg vol (10-day) 3551.92k
Shares outstanding 5108.03M
Implied shares outstanding 6N/A
Float 8103.13M
% held by insiders 12.69%
% held by institutions 187.66%
Shares short (12 May 2022) 42.18M
Short ratio (12 May 2022) 43.46
Short % of float (12 May 2022) 42.11%
Short % of shares outstanding (12 May 2022) 41.98%
Shares short (prior month 13 Apr 2022) 42.15M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022

Profitability

Profit margin 48.06%
Operating margin (ttm)55.25%

Management effectiveness

Return on assets (ttm)25.84%
Return on equity (ttm)49.75%

Income statement

Revenue (ttm)16.51B
Revenue per share (ttm)155.66
Quarterly revenue growth (yoy)17.30%
Gross profit (ttm)10.73B
EBITDA 9.41B
Net income avi to common (ttm)7.93B
Diluted EPS (ttm)70.31
Quarterly earnings growth (yoy)-12.70%

Balance sheet

Total cash (mrq)7.05B
Total cash per share (mrq)65.44
Total debt (mrq)2.7B
Total debt/equity (mrq)13.56
Current ratio (mrq)4.76
Book value per share (mrq)185.41

Cash flow statement

Operating cash flow (ttm)8.51B
Levered free cash flow (ttm)5.82B